Skip to main content
. 2020 Apr 27;40(3):231–239. doi: 10.1097/JCP.0000000000001195

FIGURE 5.

FIGURE 5

Weekly abstinence in the randomized double-blind and long-term safety studies, FAS of the double-blind study and SAS of the open-label study combined. Available data approach. Abstinence defined as negative UDS combined with TLFB negative for illicit opioid use. Participants received placebo or BUP-XR 300/300 mg or 300/100 mg at injections 1 to 6 during the double-blind study (weeks 0–25), and then the rollovers received BUP-XR 300 mg at injection 7, and BUP-XR 300 mg or 100 mg flex dosing at injections 8 to 12 (weeks 26–50) in the open-label study. De novo participants received BUP-XR 300 mg at injection 1 and BUP-XR 300 mg or 100 mg flex dosing at injections 2 to 12 (weeks 0–49) in the open-label study. TLFB, timeline follow-back; UDS, urine drug screen.